Published in N Engl J Med on July 02, 2009
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Inflammation in diabetic retinopathy. Prog Retin Eye Res (2011) 3.29
Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol (2012) 2.58
Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. Clin J Am Soc Nephrol (2012) 2.39
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int (2014) 2.22
Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev (2015) 2.19
Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol (2013) 1.77
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol (2014) 1.75
The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol (2010) 1.65
Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care (2013) 1.62
Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab (2013) 1.51
Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus. Nephrol Dial Transplant (2015) 1.49
Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes (2010) 1.48
Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol (2010) 1.43
Diabetic nephropathy. Diabetol Metab Syndr (2009) 1.43
Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc (2011) 1.43
Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol (2014) 1.33
ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther (2011) 1.32
New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. Peptides (2011) 1.32
Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol (2013) 1.30
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ (2016) 1.30
Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol (2009) 1.29
New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol (2010) 1.29
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care (2013) 1.26
Are individuals with diabetes seeing better?: a long-term epidemiological perspective. Diabetes (2010) 1.23
Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol (2010) 1.22
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis (2011) 1.18
Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep (2010) 1.16
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int (2010) 1.16
Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes (2013) 1.11
Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. Diabetes (2013) 1.09
Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep (2013) 1.09
Neurodegeneration: An early event of diabetic retinopathy. World J Diabetes (2010) 1.08
The role of cell plasticity in progression and reversal of renal fibrosis. Int J Exp Pathol (2011) 1.08
Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT). BMC Pediatr (2009) 1.08
RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol (2010) 1.07
Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy? Semin Nephrol (2012) 1.02
Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? Br J Pharmacol (2014) 1.02
eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. Am J Pathol (2009) 1.01
Inflammation and pharmacological treatment in diabetic retinopathy. Mediators Inflamm (2013) 1.00
Does tight control of systemic factors help in the management ofdiabetic retinopathy? Indian J Ophthalmol (2016) 0.99
The role of blood pressure variability in the development of nephropathy in type 1 diabetes. Diabetes Care (2010) 0.99
Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care (2012) 0.99
Anti-inflammatory therapy for diabetic retinopathy. Immunotherapy (2011) 0.98
Early diabetic nephropathy in type 1 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes (2014) 0.98
Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol (2013) 0.98
Inhibition of periostin expression protects against the development of renal inflammation and fibrosis. J Am Soc Nephrol (2014) 0.98
Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care (2015) 0.97
Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. Kidney Int (2013) 0.96
Angiotensin AT1 receptor antagonism ameliorates murine retinal proteome changes induced by diabetes. J Proteome Res (2009) 0.96
Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes. Diabetes Care (2012) 0.96
Renal protection in diabetes: lessons from ONTARGET. Cardiovasc Diabetol (2010) 0.95
Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy. PLoS One (2012) 0.95
Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes (2010) 0.94
Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol (2010) 0.94
The rise of multiple imputation: a review of the reporting and implementation of the method in medical research. BMC Med Res Methodol (2015) 0.94
Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia (2010) 0.93
High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline. Semin Nephrol (2012) 0.93
The effects of blocking Angiotensin receptors on early stages of diabetic nephropathy. Int J Prev Med (2012) 0.92
Epidemiology of hypertensive kidney disease. Nat Rev Nephrol (2010) 0.89
Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction. Int J Inflam (2012) 0.89
High rate of regression from micro-macroalbuminuria to normoalbuminuria in children and adolescents with type 1 diabetes treated or not with enalapril: the influence of HDL cholesterol. Diabetes Care (2011) 0.89
Slowing progression of chronic kidney disease. Kidney Int Suppl (2011) (2013) 0.88
Insights into substrate specificity and metal activation of mammalian tetrahedral aspartyl aminopeptidase. J Biol Chem (2012) 0.88
Pretreatment with the total flavone glycosides of Flos Abelmoschus manihot and hyperoside prevents glomerular podocyte apoptosis in streptozotocin-induced diabetic nephropathy. J Med Food (2012) 0.88
Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo. Mol Vis (2010) 0.88
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair (2011) 0.87
Suramin: a potential therapy for diabetic nephropathy. PLoS One (2013) 0.86
The relationship of retinal vessel diameter to changes in diabetic nephropathy structural variables in patients with type 1 diabetes. Diabetologia (2010) 0.86
MRI biomarkers for evaluation of treatment efficacy in preclinical diabetic retinopathy. Expert Opin Med Diagn (2013) 0.85
Angiotensin-2-mediated Ca2+ signaling in the retinal pigment epithelium: role of angiotensin-receptor-associated-protein and TRPV2 channel. PLoS One (2012) 0.85
An enzyme linked immunosorbent assay (ELISA) for the determination of the human haptoglobin phenotype. Clin Chem Lab Med (2013) 0.85
Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int (2016) 0.85
The Role of SIRT1 in Diabetic Kidney Disease. Front Endocrinol (Lausanne) (2014) 0.84
The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2011) 0.84
Global renal gene expression profiling analysis in B2-kinin receptor null mice: impact of diabetes. PLoS One (2012) 0.84
Losartan Treatment Protects Retinal Ganglion Cells and Alters Scleral Remodeling in Experimental Glaucoma. PLoS One (2015) 0.84
Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis (2015) 0.84
The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetes. Wound Repair Regen (2010) 0.84
Diabetic microvascular complications: possible targets for improved macrovascular outcomes. Int J Nephrol Renovasc Dis (2010) 0.83
Mitigating micro-and macro-vascular complications of diabetes beginning in adolescence. Vasc Health Risk Manag (2009) 0.83
The RenTg mice: a powerful tool to study renin-dependent chronic kidney disease. PLoS One (2012) 0.83
Predictors of and survival after incident stroke in type 1 diabetes. Diab Vasc Dis Res (2012) 0.83
Diabetes: hyperfiltration-a risk factor for nephropathy in T1DM? Nat Rev Endocrinol (2012) 0.82
Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension. Diabetes Obes Metab (2011) 0.82
Diabetes complications and the renin-angiotensin system. N Engl J Med (2009) 0.82
CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy. J Am Soc Nephrol (2013) 0.82
Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control. Diabetes Care (2011) 0.81
Diabetic Retinopathy-Update on Prevention Techniques, Present Therapies, and New Leads. US Ophthalmic Rev (2014) 0.80
Renal Biopsy in Type 2 Diabetic Patients. J Clin Med (2015) 0.80
The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis Tissue Repair (2010) 0.80
Prevention of diabetic kidney disease: negative clinical trials with renin-angiotensin system inhibitors. Am J Kidney Dis (2009) 0.80
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J Am Heart Assoc (2014) 0.80
Systemic medical management of diabetic retinopathy. Middle East Afr J Ophthalmol (2013) 0.80
Urinary Albumin Excretion and Vascular Function in Rheumatoid Arthritis. J Korean Med Sci (2016) 0.80
Additive Effect of Qidan Dihuang Grain, a Traditional Chinese Medicine, and Angiotensin Receptor Blockers on Albuminuria Levels in Patients with Diabetic Nephropathy: A Randomized, Parallel-Controlled Trial. Evid Based Complement Alternat Med (2016) 0.79
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med (1994) 16.24
Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med (2008) 11.61
Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology (1991) 7.27
Structural-functional relationships in diabetic nephropathy. J Clin Invest (1984) 4.78
Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol (2007) 4.48
Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol (2004) 3.38
Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis (2004) 3.11
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int (2002) 3.10
An alternative method of grading diabetic retinopathy. Ophthalmology (1986) 3.05
The early natural history of nephropathy in type 1 diabetes: I. Study design and baseline characteristics of the study participants. Diabetes (2002) 3.00
End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol (2007) 2.73
ACE-I and ARBs in early diabetic nephropathy. J Renin Angiotensin Aldosterone Syst (2002) 2.64
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet (2008) 2.49
Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes (2003) 2.16
An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int (2002) 1.80
The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes (2002) 1.79
Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol (1996) 1.74
Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes (2002) 1.70
How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol (2001) 1.65
Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol (1998) 1.64
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci (2007) 1.59
Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes (1992) 1.51
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int (2000) 1.46
The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study. Diabetes (2005) 1.40
Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia (1994) 1.40
Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: a pooled analysis. Am J Nephrol (2008) 1.19
Quantitative glomerular morphology of the normal human kidney. Lab Invest (1983) 1.18
Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol (1999) 1.10
Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia (1998) 1.08
Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol (2006) 1.05
The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study. Ophthalmology (2006) 0.96
Dietary composition and renal function in healthy subjects. Nephron (1987) 0.94
The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial. Pediatr Nephrol (2008) 0.90
Albuminuria as a surrogate marker for drug development: a European Regulatory perspective. Kidney Int Suppl (2004) 0.89
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol (2004) 13.78
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med (2013) 9.66
Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care (2012) 7.83
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42
Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA (2005) 6.87
The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol (2004) 6.53
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med (2007) 6.23
Diabetic retinopathy. N Engl J Med (2012) 5.79
Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol (2013) 5.28
Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol (2006) 4.68
The ciliary gene RPGRIP1L is mutated in cerebello-oculo-renal syndrome (Joubert syndrome type B) and Meckel syndrome. Nat Genet (2007) 4.63
The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol (2005) 4.46
Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA (2010) 4.41
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
Retinopathy in diabetes. Diabetes Care (2004) 4.25
Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med (2007) 3.94
Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med (2005) 3.92
The impact of hearing loss on quality of life in older adults. Gerontologist (2003) 3.87
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ (2012) 3.82
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol (2005) 3.74
Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology (2004) 3.53
Revised formulas for summarizing retinal vessel diameters. Curr Eye Res (2003) 3.47
Prevalence of olfactory impairment in older adults. JAMA (2002) 3.46
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet (2008) 3.42
Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry (2009) 3.33
Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology (2005) 3.28
Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. Diabetes Care (2013) 3.22
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med (2011) 3.20
Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ (2006) 3.18
Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol (2003) 3.17
The 5-year incidence and progression of hearing loss: the epidemiology of hearing loss study. Arch Otolaryngol Head Neck Surg (2003) 3.17
Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA (2013) 3.16
Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ (2010) 3.09
C-reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metab (2003) 3.04
Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care (2004) 3.03
Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care (2005) 3.02
The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes (2006) 3.00
The early natural history of nephropathy in type 1 diabetes: I. Study design and baseline characteristics of the study participants. Diabetes (2002) 3.00
Diabetic retinopathy. Diabetes Care (2004) 2.97
Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration. Am J Hum Genet (2003) 2.92
The economic burden of major adult visual disorders in the United States. Arch Ophthalmol (2006) 2.92
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 2.91
The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol (2006) 2.89
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet (2008) 2.89
Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care (2003) 2.88
A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther (2008) 2.87
Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology (2008) 2.87
Retinal vascular caliber and the development of hypertension: a meta-analysis of individual participant data. J Hypertens (2014) 2.83
Retinal vascular caliber, cardiovascular risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA). Invest Ophthalmol Vis Sci (2006) 2.79
Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA (2002) 2.78
Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA (2002) 2.72
Long-term use of aspirin and age-related macular degeneration. JAMA (2012) 2.72
Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care (2002) 2.70
The Los Angeles Latino Eye Study: design, methods, and baseline data. Ophthalmology (2004) 2.68
Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest (2012) 2.65
ACE-I and ARBs in early diabetic nephropathy. J Renin Angiotensin Aldosterone Syst (2002) 2.64
Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care (2010) 2.61
The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol (2008) 2.60
Quantitative retinal venular caliber and risk of cardiovascular disease in older persons: the cardiovascular health study. Arch Intern Med (2006) 2.60
Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes (2008) 2.60
Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ (2008) 2.52
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet (2008) 2.49
The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology (2007) 2.46
Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ (2010) 2.40
Genome-wide meta-analyses of multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. Nat Genet (2013) 2.36
The prevalence and risk factors of retinal microvascular abnormalities in older persons: The Cardiovascular Health Study. Ophthalmology (2003) 2.36
Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation (2006) 2.34
Meta-analysis of genome scans of age-related macular degeneration. Hum Mol Genet (2005) 2.34
Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) (2008) 2.29
Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis (2006) 2.29
Computer-assisted measurement of retinal vessel diameters in the Beaver Dam Eye Study: methodology, correlation between eyes, and effect of refractive errors. Ophthalmology (2004) 2.26
Generational differences in the prevalence of hearing impairment in older adults. Am J Epidemiol (2009) 2.18
Retinal arteriolar diameter and risk for hypertension. Ann Intern Med (2004) 2.18
Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis (2012) 2.17
The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum (2007) 2.16
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med (2009) 2.14
X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol (2003) 2.12
Glucose intolerance in pregnancy and future risk of pre-diabetes or diabetes. Diabetes Care (2008) 2.12
Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study. Ophthalmology (2004) 2.12
Prospective cohort study of retinal vessel diameters and risk of hypertension. BMJ (2004) 2.10
Stages of change for healthy eating in diabetes: relation to demographic, eating-related, health care utilization, and psychosocial factors. Diabetes Care (2003) 2.09
Low birthweight is associated with narrower arterioles in adults. Hypertension (2008) 2.08
Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabetes Care (2009) 2.08
Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2004) 2.08
Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care (2010) 2.08